Goflikicept PREVENTS recurrence and MAINTAINS remission in idiopathic recurrent pericarditis patients
Written By : Aditi
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2023-07-03 14:30 GMT | Update On 2023-07-03 16:03 GMT
Advertisement
An Original Investigation by Dr Valentina Yu. Myachikova, published in the Journal of the American College of Cardiology, has demonstrated the benefits of Goflikicept in idiopathic recurrent pericarditis. This anti-cytokine biologic prevents recurrence and maintains IRP remission with a favourable risk-benefit ratio, as described in the study.
It is already known that IRP is a rare autoinflammatory disease. Interleukin (IL)-1α and IL-1β are the pivotal cytokines in the pathophysiology of acute pericarditis. These are involved in its recurrence also.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.